Screener
Immunome IMNM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Immunome’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344636
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (78,135) | (46,478) | (137,466) | (91,114) |
| Interest income | 5,008 | 3,081 | 10,500 | 6,077 |
| Net loss | $(73,127) | $(43,397) | $(126,966) | $(85,037) |
| Net loss per share, basic and diluted | $(0.65) | $(0.50) | $(1.12) | $(1.02) |
| Weighted-average shares outstanding, basic and diluted | 113,272,931 | 87,010,742 | 113,205,260 | 83,231,544 |
| Comprehensive loss: | ||||
| Net loss | $(73,127) | $(43,397) | $(126,966) | $(85,037) |
| Unrealized loss on marketable securities | (333) | (21) | (333) | (81) |
Item 1. Financial Statements.
FAQ
- What is Immunome's EPS (diluted)?
- Immunome (IMNM) reported EPS (diluted) of -$0.65 in Q2 2026.
- How has Immunome's EPS (diluted) changed year-over-year?
- Immunome's EPS (diluted) decreased by 30.0% year-over-year, from -$0.50 to -$0.65.
- What is the long-term trend for Immunome's EPS (diluted)?
- Over 4 years (2021 to 2025), Immunome's EPS (diluted) has grown at a 3.2% compound annual growth rate (CAGR), from -$2.13 to -$2.42.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Immunome's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude